No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AEON AEON Biopharma
- 1.010
- -0.030-2.88%
Close Jul 2 16:00 ET
- 1.030
- +0.020+1.98%
Post 16:36 ET
39.51MMarket Cap-97P/E (TTM)
1.070High1.005Low19.91KVolume1.060Open1.040Pre Close20.45KTurnover0.12%Turnover RatioLossP/E (Static)39.12MShares17.17052wk High-0.20P/B16.23MFloat Cap0.91852wk Low--Dividend TTM16.06MShs Float17.170Historical High--Div YieldTTM6.25%Amplitude0.918Historical Low1.027Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $6 Price Target
Buy Rating Affirmed for AEON Biopharma: Strategic Cost-Cutting and ABP-450's Broad Market Potential
Express News | AEON Biopharma Shares Are Trading Higher After the Company Announced a Resource Prioritization and Cost Reduction Plan
AEON Biopharma Shares Jump on Job Cuts, CFO Firing
By Dean Seal Shares of AEON Biopharma climbed after the company said it laid off more than half of its staff, including its chief financial officer, so as to extend its cash runway through the end of
AEON Biopharma: Cost-Reduction Actions to Include Efforts to Cut Additional Operating Costs, Expected to Be Substantially Completed by June 2024 >AEON
AEON Biopharma: Cost-Reduction Actions to Include Efforts to Cut Additional Operating Costs, Expected to Be Substantially Completed by June 2024 >AEON
AEON Biopharma Names Corporate Controller Jennifer Sy as Principal Acctg Officer >AEON
AEON Biopharma Names Corporate Controller Jennifer Sy as Principal Acctg Officer >AEON
Comments
$AEON Biopharma(AEON.US$ it will go up
$AEON Biopharma(AEON.US$ coming off the watchlist. Company has never turned a profit since it started (common enough for pharmaceutical R&D company like this), quarterly report seems to confirm their flagship product development is ineffective. Company will need to do some serious cap raising to stay afloat. Leave this one and take your money elsewhere.
3
$AEON Biopharma(AEON.US$ on the watchlist, phase 2 trial seemed okay other than unexpectedly strong result from placebo, interested to see how phase 3 goes. Might look to enter if price goes lower.
4
$AEON Biopharma(AEON.US$
this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
![]()
this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
3
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg